BL is aiming to adopt an indication expansion strategy and develop 'BLS-H01,’ its new drug for COVID-19 treatment for which a Phase II trial is underway, as a broad-spectrum treatment for pneumonia.

According to BL on the 5th, BLS-H01 is an immunoregulatory treatment that contains a gamma PGA. A clinical trial is currently underway to assess its effect in preventing and treating pneumonia caused by COVID-19.

BLS-H01’s core ingredient, ‘gamma PGA,’ stimulates the expression of dendritic cells that are necessary for the activation of natural killer (NK) cells and immune T cells to promptly remove virus-infected cells in the lung.

This mechanism of action can respond to